Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration

被引:50
作者
Ramirez, JC
Finke, D
Esteban, M
Kraehenbuhl, JP
Acha-Orbea, H
机构
[1] CSIC, Ctr Nacl Biotecnol, Madrid, Spain
[2] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland
[3] Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland
[4] Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland
关键词
D O I
10.1007/s00705-003-0006-z
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
MVA is a candidate vector for vaccination against pathogens and tumors. Little is known about its behaviour in mucosal tissues. We have investigated the fate and biosafety of MVA, when inoculated by different routes in C57BL/6 mice. Intranasal inoculation targeted the virus to the nasal associated lymphoid tissue and the lungs, whereas systemic inoculation led to distribution of MVA in almost all lymphoid organs, lungs and ovaries. Intravaginal, intrarectal and intragastric inoculations failed to induce efficient infection. After 48 h no virus was detectable any more in the organs analyzed. Upon intranasal inoculation, no inflammatory reactions were detected in the central nervous system as well as the upper and lower airways. These results show the tropism of MVA and indicate that high doses of recombinant MVA are safe when nasally administered, a vaccination route known to elicit strong cellular and humoral immune responses in the female genital tract.
引用
收藏
页码:827 / 839
页数:13
相关论文
共 42 条
[1]   PARTIAL DELETION OF THE HUMAN HOST RANGE GENE IN THE ATTENUATED VACCINIA VIRUS MVA [J].
ALTENBURGER, W ;
SUTER, CP ;
ALTENBURGER, J .
ARCHIVES OF VIROLOGY, 1989, 105 (1-2) :15-27
[2]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[3]   Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination [J].
Barouch, DH ;
Santra, S ;
Kuroda, MJ ;
Schmitz, JE ;
Plishka, R ;
Buckler-White, A ;
Gaitan, AE ;
Zin, R ;
Nam, JH ;
Wyatt, LS ;
Lifton, MA ;
Nickerson, CE ;
Moss, B ;
Montefiori, DC ;
Hirsch, VM ;
Letvin, NL .
JOURNAL OF VIROLOGY, 2001, 75 (11) :5151-5158
[4]   Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity [J].
Belyakov, IM ;
Moss, B ;
Strober, W ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4512-4517
[5]   Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein [J].
Belyakov, IM ;
Wyatt, LS ;
Ahlers, JD ;
Earl, P ;
Pendleton, CD ;
Kelsall, BL ;
Strober, W ;
Moss, B ;
Berzofsky, JA .
JOURNAL OF VIROLOGY, 1998, 72 (10) :8264-8272
[6]   Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza [J].
Bender, BS ;
Rowe, CA ;
Taylor, SF ;
Wyatt, LS ;
Moss, B ;
Small, PA .
JOURNAL OF VIROLOGY, 1996, 70 (09) :6418-6424
[7]   Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine [J].
Blanchard, TJ ;
Alcamí, A ;
Andrea, P ;
Smith, GL .
JOURNAL OF GENERAL VIROLOGY, 1998, 79 :1159-1167
[8]   Induction of mucosal homing virus-specific CD8+ T lymphocytes by attenuated simian immunodeficiency virus [J].
Cromwell, MA ;
Veazey, RS ;
Altman, JD ;
Mansfield, KG ;
Glickman, R ;
Allen, TM ;
Watkins, DI ;
Lackner, AA ;
Johnson, RP .
JOURNAL OF VIROLOGY, 2000, 74 (18) :8762-8766
[9]   Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes [J].
Dupuy, C ;
Buzoni-Gatel, D ;
Touzé, A ;
Bout, D ;
Coursaget, P .
JOURNAL OF VIROLOGY, 1999, 73 (11) :9063-9071
[10]   The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys [J].
Durbin, AP ;
Wyatt, LS ;
Siew, J ;
Moss, B ;
Murphy, BR .
VACCINE, 1998, 16 (13) :1324-1330